MARKET

AVXL

AVXL

Anavex Life
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.41
-0.82
-4.26%
After Hours: 18.50 +0.09 +0.49% 16:00 09/28 EDT
OPEN
18.80
PREV CLOSE
19.23
HIGH
18.80
LOW
18.35
VOLUME
721.37K
TURNOVER
--
52 WEEK HIGH
31.50
52 WEEK LOW
3.950
MARKET CAP
1.39B
P/E (TTM)
-38.0529
1D
5D
1M
3M
1Y
5Y
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...
GlobeNewswire · 1d ago
BRIEF-Anavex Life Sciences Announces Uplisting To The Nasdaq Global Select Market
reuters.com · 1d ago
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market(R)
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...
GlobeNewswire · 1d ago
BTIG Initiates Coverage On Anavex Life Sciences with Buy Rating, Announces Price Target of $35
BTIG analyst Yun Zhong initiates coverage on Anavex Life Sciences (NASDAQ:AVXL) with a Buy rating and announces Price Target of $35.
Benzinga · 5d ago
Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmen...
GlobeNewswire · 09/20 11:00
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...
GlobeNewswire · 09/09 11:00
Anavex Life Sciences Granted U.S. Patent Titled 'Anavex2-73 for the treatment of alzheimer's disease'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6666&f=G&l=50&d=PTXT&p=134&S1=20210831&OS=20210831&RS=20210831
Benzinga · 08/31 13:34
Anavex Life Sciences Says Fragile X Syndrome Treatment Was Effective in Mice in Preclinical Study
MT Newswires · 08/26 13:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVXL. Analyze the recent business situations of Anavex Life through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AVXL stock price target is 38.29 with a high estimate of 50.00 and a low estimate of 30.75.
High50.00
Average38.29
Low30.75
Current 18.41
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 145
Institutional Holdings: 25.68M
% Owned: 33.91%
Shares Outstanding: 75.71M
TypeInstitutionsShares
Increased
42
3.65M
New
35
1.30M
Decreased
27
1.08M
Sold Out
17
569.07K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.66%
Pharmaceuticals & Medical Research
-1.98%
Key Executives
Chairman/President/Chief Executive Officer/Secretary/Director
Christopher Missling
Chief Financial Officer/Treasurer
Sandra Boenisch
Senior Vice President
Adebayo Laniyonu
Lead Director/Independent Director
Claus van der Velden
Director
Jiong Ma
Independent Director
Peter Donhauser
Independent Director
Athanasios Skarpelos
Independent Director
Steffen Thomas
No Data
  • All
  • Financials
  • Insiders
More
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.

Webull offers kinds of Anavex Life Sciences Corp stock information, including NASDAQ:AVXL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVXL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVXL stock methods without spending real money on the virtual paper trading platform.